Camzyos(mavacamten) Instructions:Uses,Dosage, Side Effects

CAMZYOS (mavacamten) is an oral, allosteric, and reversible cardiac myosin inhibitor designed to modulate the number of myosin heads entering power-generating states, thereby reducing excessive contractility characteristic of hypertrophic cardiomyopathy. By selectively targeting cardiac myosin, CAMZYOS decreases left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures, addressing the underlying pathophysiology of obstructive HCM.

The pharmacological action of CAMZYOS results in a dose-dependent reduction in LVOT gradients and improvement in exercise capacity and symptoms, as demonstrated in clinical trials. Due to its potential to cause systolic dysfunction and heart failure, careful patient selection, regular echocardiographic monitoring, and adherence to the CAMZYOS REMS Program are mandatory to ensure safe administration. The safety and efficacy in populations outside the specified indication, including pediatric and pregnant patients, are not specified in the specification.